Human Anti-Oxidation Protein A1M-A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy.
Ahlstedt, Jonas LU ; Tran, Thuy LU ; Strand, Sven-Erik LU ; Gram, Magnus LU
and Åkerström, Bo
LU
(2015)
In International Journal of Molecular Sciences
16(12).
p.30309-30320
- Abstract
- Peptide receptor radionuclide therapy (PRRT) has been in clinical use for 15 years to treat metastatic neuroendocrine tumors. PRRT is limited by reabsorption and retention of the administered radiolabeled somatostatin analogues in the proximal tubule. Consequently, it is essential to develop and employ methods to protect the kidneys during PRRT. Today, infusion of positively charged amino acids is the standard method of kidney protection. Other methods, such as administration of amifostine, are still under evaluation and show promising results. α₁-microglobulin (A1M) is a reductase and radical scavenging protein ubiquitously present in plasma and extravascular tissue. Human A1M has antioxidation properties and has been shown to prevent... (More)
- Peptide receptor radionuclide therapy (PRRT) has been in clinical use for 15 years to treat metastatic neuroendocrine tumors. PRRT is limited by reabsorption and retention of the administered radiolabeled somatostatin analogues in the proximal tubule. Consequently, it is essential to develop and employ methods to protect the kidneys during PRRT. Today, infusion of positively charged amino acids is the standard method of kidney protection. Other methods, such as administration of amifostine, are still under evaluation and show promising results. α₁-microglobulin (A1M) is a reductase and radical scavenging protein ubiquitously present in plasma and extravascular tissue. Human A1M has antioxidation properties and has been shown to prevent radiation-induced in vitro cell damage and protect non-irradiated surrounding cells. It has recently been shown in mice that exogenously infused A1M and the somatostatin analogue octreotide are co-localized in proximal tubules of the kidney after intravenous infusion. In this review we describe the current situation of kidney protection during PRRT, discuss the necessity and implications of more precise dosimetry and present A1M as a new, potential candidate for renal protection during PRRT and related targeted radionuclide therapies. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8503923
- author
- Ahlstedt, Jonas
LU
; Tran, Thuy
LU
; Strand, Sven-Erik
LU
; Gram, Magnus
LU
and Åkerström, Bo
LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Molecular Sciences
- volume
- 16
- issue
- 12
- pages
- 30309 - 30320
- publisher
- MDPI AG
- external identifiers
-
- pmid:26694383
- wos:000367535600151
- scopus:84950125870
- pmid:26694383
- ISSN
- 1422-0067
- DOI
- 10.3390/ijms161226234
- language
- English
- LU publication?
- yes
- id
- 9ad76ccc-8d79-402c-bfdf-9abb2ed2a9bb (old id 8503923)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26694383?dopt=Abstract
- date added to LUP
- 2016-04-01 14:21:59
- date last changed
- 2022-01-28 00:13:13
@article{9ad76ccc-8d79-402c-bfdf-9abb2ed2a9bb,
abstract = {{Peptide receptor radionuclide therapy (PRRT) has been in clinical use for 15 years to treat metastatic neuroendocrine tumors. PRRT is limited by reabsorption and retention of the administered radiolabeled somatostatin analogues in the proximal tubule. Consequently, it is essential to develop and employ methods to protect the kidneys during PRRT. Today, infusion of positively charged amino acids is the standard method of kidney protection. Other methods, such as administration of amifostine, are still under evaluation and show promising results. α₁-microglobulin (A1M) is a reductase and radical scavenging protein ubiquitously present in plasma and extravascular tissue. Human A1M has antioxidation properties and has been shown to prevent radiation-induced in vitro cell damage and protect non-irradiated surrounding cells. It has recently been shown in mice that exogenously infused A1M and the somatostatin analogue octreotide are co-localized in proximal tubules of the kidney after intravenous infusion. In this review we describe the current situation of kidney protection during PRRT, discuss the necessity and implications of more precise dosimetry and present A1M as a new, potential candidate for renal protection during PRRT and related targeted radionuclide therapies.}},
author = {{Ahlstedt, Jonas and Tran, Thuy and Strand, Sven-Erik and Gram, Magnus and Åkerström, Bo}},
issn = {{1422-0067}},
language = {{eng}},
number = {{12}},
pages = {{30309--30320}},
publisher = {{MDPI AG}},
series = {{International Journal of Molecular Sciences}},
title = {{Human Anti-Oxidation Protein A1M-A Potential Kidney Protection Agent in Peptide Receptor Radionuclide Therapy.}},
url = {{http://dx.doi.org/10.3390/ijms161226234}},
doi = {{10.3390/ijms161226234}},
volume = {{16}},
year = {{2015}},
}